<![CDATA[CorFlow Therapeutics AG 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=46310>Thu, 16 Apr 2026 05:39:38 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology]]>https://www.newswire.co.kr/newsRead.php?no=1014525Tue, 08 Jul 2025 15:10:00 +0900<![CDATA[코플로우 테라퓨틱스, 새로운 심장마비 치료 기술 검증을 위한 MOCA-II IDE 중추적 시험에 대한 FDA 승인 발표]]>https://www.newswire.co.kr/newsRead.php?no=1014527Tue, 08 Jul 2025 15:10:00 +0900<![CDATA[CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors]]>https://www.newswire.co.kr/newsRead.php?no=1010678Wed, 07 May 2025 17:00:00 +0900<![CDATA[코플로우 테라퓨틱스, 크리스 오코넬을 이사회 회장으로 임명]]>https://www.newswire.co.kr/newsRead.php?no=1010679Wed, 07 May 2025 17:00:00 +0900<![CDATA[CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients]]>https://www.newswire.co.kr/newsRead.php?no=996672Wed, 11 Sep 2024 11:05:00 +0900<![CDATA[코플로우 테라퓨틱스, 4400만유로 규모의 시리즈 B 펀딩 완료로 심장마비 환자의 미세혈관폐색을 위한 새로운 진단 및 약물 전달 플랫폼 개발 지원]]>https://www.newswire.co.kr/newsRead.php?no=996674Wed, 11 Sep 2024 11:05:00 +0900